Current Month 2007
Article Features
  Study Finds Difference in Survival Rates Among White and Black Women with Advanced Breast Cancer
Drug Shows Activity Against Brain Metastases
Brain-Boosting Pill Alleviates Post-Chemotherapy Fogginess
Diet and Exercise Key to Surviving Breast Cancer, Regardless of Obesity
Effect on Breast Tumors of DNA Alterations in 3 Genes Described
Simple Steps Make Breast Cancer Survivors Eager to Exercise
Study Supports Activity of GEMZAR in the Treatment of Early-Stage Breast Cancer
First Confirmed Common Genetic Risk for Breast Cancer
Genetic Markers in Surrounding Tissues Linked to Breast Cancer Tumor Grade, Presence of Metastases
Hair Straightening Chemicals Not Linked to Breast Cancer Risk in African-Americans
Study Suggests Newer Breast Cancer Drug May Protect Heart
Study Confirms Long-Term Benefits of Herceptin plus Chemotherapy
Hot Flashes May Be Welcome Sign in Women with Breast Cancer
Reducing Cardiovascular Disease Risk Factors When Discontinuing Hormone Replacement Therapy
Alternative Breast Imaging Techniques Sort Abnormal from Normal Tissue
Follow-up Care for Breast Cancer Patients is Inconsistent
Inflammation Protein Is Not Associated With Breast Cancer Risk
Exercise Lowers Insulin in Breast Cancer Survivors
Women Well Informed About Breast Cancer Yet Lacking Knowledge About Current Treatments
Mammography Rates Declining in the United States
MRI Detects Cancer Missed by Mammography in Breast Cancer Patients
Breast MRI May Help Determine Surgical Management of Women with Newly Diagnosed Breast Cancer
Increasing Radiation Dose Shortens Treatment Time for Women Who Choose Breast Sparing Treatment
Sensitivity to Diverse Range of Chemotherapeutic Drugs Linked to Common Pathway
Panel Offers Guidelines on Skin Reactions to New Class of Cancer Drugs
Tumor Cell Activity May Provide Clues for Treating Breast Cancer in Young Women


Study Finds Herceptin Does Not Increase Risk of Heart Failure in Patients

The risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31. The results were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy.

"The information we obtained from this study is essential to understanding women's risks for congestive heart failure associated with adding Herceptin to combination chemotherapy for breast cancer treatment," said Priya Rastogi, M.D., assistant professor, University of Pittsburgh School of Medicine and assistant director of medical affairs, NSABP. "We're encouraged that we found no increase in heart failure risks long-term and now are able to use this knowledge to individualize women's treatment based on their specific cardiac risk factors."

Read More of the Main Article

Intake of Vitamin D and Calcium Associated with Lower Risk of Breast Cancer Before Menopause

Women who consume higher amounts of calcium and vitamin D may have a lower risk of developing premenopausal breast cancer, according to a report in the journal Archives of Internal Medicine.

Data from animal studies have linked calcium and vitamin D to breast cancer prevention, according to background information in the article. However, epidemiologic studies on humans have been less conclusive.

Jennifer Lin, Ph.D., of Brigham and Women's Hospital and Harvard Medical School, Boston, and colleagues assessed 10,578 premenopausal and 20,909 postmenopausal women age 45 and older who were part of the Women's Health Study. At the beginning of the study (in 1993 or 1995), the women completed a questionnaire about their medical history and lifestyle, plus a food frequency questionnaire that detailed how often they consumed certain foods, beverages and supplements during the previous year. Every six months during the first year and then every year after that, participants returned follow-up questionnaires indicating whether they had been diagnosed with breast cancer.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon